Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC.
Zhou Q, Soo RA, Chang GC, Chiu CH, Hayashi H, Kim SW, Teraoka S, Goto Y, Zhou J, Ho-Fun Lee V, Kim DW, Han B, Chung Man Ho J, Lin CC, Lu S, Polli A, Calella AM, Martini JF, Wong CH, Mok T, Kim HR, Wu YL. Zhou Q, et al. Among authors: polli a. JTO Clin Res Rep. 2023 Mar 11;4(5):100499. doi: 10.1016/j.jtocrr.2023.100499. eCollection 2023 May. JTO Clin Res Rep. 2023. PMID: 37223611 Free PMC article.
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Lønning PE, et al. Among authors: polli a. J Clin Oncol. 2005 Aug 1;23(22):5126-37. doi: 10.1200/JCO.2005.07.097. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983390 Clinical Trial.
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G. Kaufmann M, et al. Among authors: polli a. Clin Breast Cancer. 2000 Sep;1 Suppl 1:S15-8. doi: 10.3816/cbc.2000.s.003. Clin Breast Cancer. 2000. PMID: 11970744 Clinical Trial.
Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group.
Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, L'Hermite M, Ciccarelli E, et al. Webster J, et al. Among authors: polli a. Clin Endocrinol (Oxf). 1992 Dec;37(6):534-41. doi: 10.1111/j.1365-2265.1992.tb01485.x. Clin Endocrinol (Oxf). 1992. PMID: 1286524 Clinical Trial.
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.
Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J. Geisler J, et al. Among authors: polli a. Eur J Cancer. 2006 Nov;42(17):2968-75. doi: 10.1016/j.ejca.2006.07.005. Epub 2006 Sep 11. Eur J Cancer. 2006. PMID: 16963261 Clinical Trial.
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G. Lønning PE, et al. Among authors: polli a. J Clin Oncol. 2000 Jun;18(11):2234-44. doi: 10.1200/JCO.2000.18.11.2234. J Clin Oncol. 2000. PMID: 10829043 Clinical Trial.
86 results